Member Info for Retireby40

But ultimately this is the AiM and I bet the CEO didn’t think they’d raise money or feel the need to when he gave his results presentation. The share price has appreciated a lot since then and he’d have a lot of advisors telling him he’d be stilly not to. I’m sure it’ll be over subscribed and they’ve given retail shareholders a bite of the cherry and my bet is, like the last raise (not long ago!) this will be well above the raise price in multiples in a similar timeframe.

Considering where the co is gojng it’s short term pain for long and probably medium/short term gain.

Clearly but you’re looking a bit pathetic. I said the same as you, look back but I’m not looking for apologies or gloating.

Anyway, it’s not as disastrous as some think. It may drop before bouncing and I get closes early as over subscribed.

Don’t be a dick about it dryland

I’m not de-ramping I’m simply saying given the price action it looks liken there could be one. I wouldn’t have thought this a week ago but the price action seems more than fear and a sell off as many buys too but it’s dropped and dropped. Let’s see but if there is one they’ll want some solid reasons. Logging off and will see what tomorrow brings.

Agreed, dryland. From advfn -If there is one I agree it’d be more like 120p than 140p. It’d be surprising but this is the AiM and if they see it too good an opportunity to not raise funds at this level and it’d be used to accelerate some other programs it’s short term pain re share price for longer term gain.

If they did so it’s strange not to do so after news on the tests but perhaps they don’t wanna take any risks and at a much higher price they might not get it away. Who knows. Hope it’s not the case but if so they’ll need to give some solid reasons as to why to get many holders back on side given the CEO said there wouldn’t be one not so long ago.

https://mcusercontent.com/d9ebd7c1aa0f3dbc5fab42eca/files/c3c405a7-e232-4ed7-b30d-f83cd435faba/Integumen_Research_Update_3_June_2020__FINAL_BG.pdf

Some snippets but full note above .

Having already been contracted to supply European bacteria reagent manufacturing capacity together with the provision of logistical support for Modern Water’s (AIM:MWG) sales, marketing and distribution in the US, EU, China and Japan, Integumen has demonstrated its ability to apply its unique services and technologies to rapidly identify and respond to the urgent needs being presented by the global Pandemic. Today’s further initiative potentially opens significant new and long-term market opportunities that simply did not exist just a few months ago. With the weight of anticipated demand from global-scale manufacturers seen likely to test the Group’s expanded laboratory capacity before the end of current period financial year, TPI’s Initiation research on Integumen plc (released on 9th January 2020) set a target price of 3.23p/share.

In May 2020, a pilot study run by the Surrey Perioperative Anaesthesia & Critical Care Collaborative Research Group at the Royal Surrey County Hospital commenced an investigation as to the ability of povidone-iodine (PVP-I) 0.5% aqueous solution oral/nasal spray and mouthwash to kill the SARS-CoV-2 virus in people with COVID-19. While complicated by problems with the recruitment and administration of patients in a clinical setting, this study is designed to test the hypothesis, as was highlighted in a press briefing by the US’s President Trump back in May, that a common medical disinfectant, administered to the mouth and nose of confirmed COVID-19 sufferers has potential to reduce the quantity of the virus in the fluid lining those areas.

Demonstration of this through the tests now to be undertaken at the University of Aberdeen (as detailed in today’s announcement, has potential to generate significant interest for such an ‘off-the-shelf’ solution from researchers, manufacturers and agencies around the world.

https://twitter.com/gjbrandon/status/1268088229577863169?s=21

If only it were a simple process. This has taken many weeks on health and safety, protocols, design of research projects (as there are more than disclosed in RNS, not material) ethics committees, university committees and weighed on priorities of virus testing for other projects

Fantastic news and will tricky to get access to such labs so well done SKIN. It’ll get them on many radars, imagine clients being able to claim their product kills 99.9999% of the virus etc. I’m sure cos won’t want their names revealed yet in case their products aren’t effective but once one works they’ll all want testing. Massive potential.

I imagine this will be step 1 and once the real-.time Water monitoring prototype is completed and they have access to the right reagents for Covid they’ll have to test in cat 3 labs so onwards and upwards. Exciting times and remember they’ve worked with pathogens, Ebola for one so are experienced.

2 MMs buying at 2p

I agree the photoshopping is ridiculous and doesn’t look good. He should really take it down as it’s too much.

The team of shorters. News is due any day so trying to trade is dangerous, although less likely we could get an intraday RNS. Alastair suggested it’d take a few weeks to get the prototypes and the BAMS likely first and they both received the Affimers 3 weeks yesterday. It also took Cytiva 4 weeks to develop Sona’s test (ours will smash it for accuracy) so expect a Adeptrix RNS in the next few days followed by a Cytiva one and then I imagine plenty of new partners will be RNS’d.

An exciting couple of weeks ahead and news likely in the next week. Am holding long and strong. Ignore the noise, a clear agenda or they wouldn’t be posting incessantly.

The team of shorters. News is due any day so trying to trade is dangerous, although less likely we could get an intraday RNS. Alastair suggested it’d take a few weeks to get the prototypes and the BAMS likely first and they both received the Affimers 3 weeks today. It also took Cytiva 4 weeks to develop Sona’s test (ours will smash it for accuracy) so expect a Adeptrix RNS in the next few days followed by a Cytiva one and then I imagine plenty of new partners will be RNS’d.

An exciting couple of weeks ahead and news likely in the next week. Am holding long and strong. Ignore the noise, a clear agenda or they wouldn’t be posting incessantly.

Good work!

Coronavirus infections in hospitals and care homes are spilling into the community and sustaining the outbreak to the point that cases will remain steady until September, a leading scientist has warned.

https://www.theguardian.com/world/2020/jun/02/covid-19-spilling-out-of-hospitals-and-care-homes-says-uk-expert?CMP=share_btn_fb

Yep so we should have BAMS news any day and all being well Cytiva next week. Exciting times and amazing some are selling but I guess profit is profit.

Didn’t Alastair say the expectation was for the prototypes to take 3 weeks and BAMS more likely the first one to to developed to the required standard? If so it’s 3 weeks today when Adeptrix and Cytiva would’ve received them so hopefully BAMS news this week (I imagine closely followed by manufacturer deals being signed and RNS’d) and not long after Cytiva. So I’m not sure why you think -

1. BAMS with Adeptrix – this is due first as it is much easier to develop and certify. This was announced on the 1st May and the Affimers shipped on 11th May. If we say 6 weeks then 20th June would be likely the date.
2. LFA with Cytiva – This was announced on the 8th April and the Affimers were shipped on 11th May as above. If this takes 8 weeks to prototype, develop and certify which is fast, then we would see a date of around 6th July.

Gerard J Brandon

#Integumen have been talking to OEM producers of electronic equipment to enable the roll out of mass production volumes once the miniaturisation process testing using the SARS-CoV-2 is complete.

https://twitter.com/gjbrandon/status/1267516098024480768?s=21

RE: Cruise ShipsToday 14:28
@somersetgreen There are many infectious diseases and you touch on just two - Norovirus and SARS-CoV-2, but up to 150 viruses can exist in Blackwater (waste from toilets that contain pathogens). Depending on the position of the detection unit a cruise ship may be able to identify a deck, a row of cabins or a column, assuming each floor includes the toilets in a stack from lower to higher deck.

As for identification, each pathogen binding agent is very specific to the target. The units will be single (1 target) detection or multiple as an in-line series of 4 for up to 4 pathogenic targets. If an alert is triggered, the crew doctor will be able to isolate the hotspot and individually test passenger cabin occupants before it spreads and isolate accordingly.

Once the detection occurs it will be necessary to replace the optical glass unit in the cartridge. It is not possible to insert an image here but you can see what I mean from the 3D animation and the image of the optical glass with the binding agent attached. here

https://twitter.com/gjbrandon/status/1267447643619364864?s=20

https://twitter.com/gjbrandon/status/1266014306329669635?s=20

https://twitter.com/gjbrandon/status/1267448498724786178?s=21

https://twitter.com/gjbrandon/status/1266014306329669635?s=21